

Disclosure of Transfers of Value Methodology Note for Tetris Pharma 2024

Tetris Pharma Methodology, 2024

Tetris Pharma is a specialty pharmaceutical business focused on taking branded medicines to market as well as distributing niche injectable products. During 2024 one branded and five generic products were marketed by Tetris Pharma solely in the UK. No research and educational grants and donations were made. Tetris Pharma had no active product development programmes in 2024. All payments during the chronological year 2024 were reviewed. The total spending was reviewed with finance functions. The aggregated total is declared on the accompanying spread sheet.

In collating disclosure data, the following methodologies have been used:

- Amounts declared included VAT applied.
- Amounts declared are in UK sterling.
- There were no other payments worldwide.
- Contracts were for a single year of 2024.
- Tetris Pharma does not have any over-the-counter business or medical device business.
- Individual consent has been sought for individual payments to healthcare professionals with no refusals.
- Tetris Pharma has made no non-monetary transfers of value in 2024
- Tetris Pharma has no joint working to disclose in 2024
- Tetris Pharma made no Grants or Donations to patient groups in 2024.